<DOC>
	<DOC>NCT00555841</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy and safety of ALC in the treatment of non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant radiotherapy.</brief_summary>
	<brief_title>Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue</brief_title>
	<detailed_description>The objective of this study is to evaluate the efficacy and safety of ALC in the treatment of non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant radiotherapy</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<criteria>Stage 0III breast cancer in which adjuvant radiation is indicated; Qualifying Brief Fatigue Inventory (BFI) score 6. Medication to treat or manage fatigue and pain Use of erythropoietin to control anemia Clinical evidence of hypothyroidism or hyperthyroidism</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>breast cancer</keyword>
</DOC>